Welcome to our dedicated page for VOLITIONRX SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VOLITIONRX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VOLITIONRX's regulatory disclosures and financial reporting.
Transaction summary: Ann-Louise Batchelor, Group Chief Marketing Officer, filed a Form 4 for VolitionRx Ltd (VNRX) reporting activity dated 08/01/2025.
Details: The filing states 18,341 restricted stock units were settled in lieu of cash compensation and that 8,620 shares were retained by VolitionRx for cancellation to satisfy the reporting person’s tax withholding obligations. The filing explicitly states no shares were sold. Following the reported transaction, Batchelor beneficially owns 132,486 shares directly and 29,406 shares indirectly (by spouse). The table shows a price of $0.64. Form signed 08/05/2025.
VolitionRx Ltd. (VNRX) – Form 4 filing
Chief Commercial Officer Gael Forterre reported a single Code F transaction on 1 Aug 2025, reflecting shares surrendered to the company to cover taxes upon settlement of 6,690 restricted stock units received in lieu of cash compensation. 2,766 common shares were withheld at an implied price of $0.64 and therefore cancelled; no open-market sale occurred.
Following the withholding, Forterre’s holdings stand at 156,700 directly-owned shares. He also reports 5,000 shares held indirectly by his spouse and 32,500 shares managed through Armorica Partners, LLC, over which he exercises voting and dispositive control. The filing represents routine administrative tax withholding and does not signal a change in insider ownership intent or corporate outlook.